Regeneron Pharmaceuticals, Inc. — Wall Street Analyst Estimates & Price Targets

REGN

NASDAQHealthcareBiotechnologyCIK 0000872589regeneron.comAbout REGN

Last close · Oct 16, 2026790.74−5.60 (−0.70%)

Market cap$81.4B

15 firms' latest targets, last 90 days: median $824.00 ($750.00–$1,030.00), 4% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 15 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-14	UBS	$978.00	—	—	+26%	+24%
2026-10-08	RBC Capital	$810.00	$737.00	▲ 10%	+11%	+2%
2026-10-08	Raymond James	$911.00	$910.00	= 0%	+23%	+15%
2026-10-07	Truist	$780.00	$769.00	▲ 1%	+4%	-1%
2026-10-07	Morgan Stanley	$779.00	$758.00	▲ 3%	+5%	-1%
2026-10-01	Jefferies	$930.00	—	—	+25%	+18%
2026-10-01	BMO Capital	$920.00	$730.00	▲ 26%	+24%	+16%
2026-10-01	Argus Research	$850.00	—	—	+12%	+7%
2026-09-10	HSBC	$920.00	$800.00	▲ 15%	+14%	+16%
2026-08-17	Leerink Partners	$824.00	$641.00	▲ 29%	+3%	+4%
2026-08-14	Bernstein	$756.00	$921.00	▼ 18%	-5%	-4%
2026-08-03	Guggenheim	$1,030.00	$1,000.00	▲ 3%	+35%	+30%
2026-07-31	Cantor Fitzgerald	$795.00	$750.00	▲ 6%	+7%	+1%
2026-07-31	Baird	$761.00	$742.00	▲ 3%	+3%	-4%
2026-07-31	Wells Fargo	$750.00	$700.00	▲ 7%	+2%	-5%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$13.1B	+8%	$34.77	-9%	est. $12.9B+1%	est. $42.62	16
2024reported	$14.2B	+8%	$38.34	+10%	est. $14.2B+0%	est. $44.90	17
2025reported	$14.3B	+1%	$41.48	+8%	est. $14.3B+1%	est. $43.48	16
2026	$17.5B	+22%	$58.36	+34%	$15.8B–$19.0B	$44.14–$64.68	19
2027	$18.8B	+7%	$62.54	+7%	$17.0B–$20.2B	$51.52–$67.36	17
2028	$20.1B	+7%	$69.64	+11%	$17.7B–$22.6B	$61.42–$78.31	20
2029	$21.4B	+6%	$75.64	+9%	$18.8B–$23.1B	$63.97–$83.75	10
2030	$22.5B	+5%	$80.25	+6%	$19.8B–$24.3B	$67.87–$88.86	10

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$824.00median target, 4% above the last close

Firms with a target · last 90 days: 15
Lowest – highest target: $750.00 – $1,030.00
Current grades of 24 firms: positive / neutral / negative: 18 / 6 / 0
Upgrades / downgrades · 12 months: 4 / 3
Consensus revenue growth · next 3 FY: +12% a year

Current grades

each firm's latest · 24 firms

As of	Firm	Grade
2026-10-15	UBS	“Buy”
2026-10-08	RBC Capital	“Sector Perform”
2026-10-07	Truist	“Buy”
2026-10-07	Morgan Stanley	“Equal Weight”
2026-10-06	J.P. Morgan	“Overweight”
2026-10-01	Argus Research	“Buy”
2026-10-01	Jefferies	“Buy”
2026-09-10	HSBC	“Buy”
2026-08-17	Leerink Partners	“Market Perform”
2026-08-03	Guggenheim	“Buy”

14 more

2026-08-03	Citigroup	“Neutral”
2026-07-31	Wells Fargo	“Equal Weight”
2026-07-31	Cantor Fitzgerald	“Overweight”
2026-07-09	Piper Sandler	“Overweight”
2026-07-07	Benchmark	“Buy”
2026-05-19	Canaccord Genuity	“Buy”
2026-05-18	BMO Capital	“Outperform”
2026-04-30	Barclays	“Overweight”
2026-04-23	TD Cowen	“Buy”
2026-04-08	Bernstein	“Outperform”
2026-02-02	Oppenheimer	“Outperform”
2026-01-22	Evercore ISI	“Outperform”
2026-01-07	Bank of America	“Buy”
2025-11-24	Scotiabank	“Sector Perform”

Grade changes

last 24 months · 11

Date	Firm	Grade
2026-10-15	UBS	“Neutral” → “Buy” upgrade
2026-10-01	Argus Research	“Hold” → “Buy” upgrade
2026-07-07	Benchmark	“Hold” → “Buy” upgrade
2026-05-18	Citigroup	“Buy” → “Neutral” downgrade
2026-05-18	Leerink Partners	“Outperform” → “Market Perform” downgrade
2026-01-07	Bank of America	“Underperform” → “Buy” upgrade
2025-12-03	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2025-05-30	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2025-05-14	Citigroup	“Neutral” → “Buy” upgrade
2025-02-05	Leerink Partners	“Market Perform” → “Outperform” upgrade
2025-01-16	UBS	“Buy” → “Neutral” downgrade

49 older than 24 months

2024-09-24	Leerink Partners	“Outperform” → “Market Perform” downgrade
2024-01-12	RBC Capital	“Sector Perform” → “Outperform” upgrade
2023-11-03	Raymond James	“Market Perform” → “Outperform” upgrade
2023-08-21	Canaccord Genuity	“Hold” → “Buy” upgrade
2023-06-28	Canaccord Genuity	“Buy” → “Hold” downgrade
2023-05-16	RBC Capital	“Sector Perform” → “Perform” revised
2023-03-27	Leerink Partners	“Market Perform” → “Outperform” upgrade
2023-03-24	Jefferies	“Hold” → “Buy” upgrade
2023-03-24	Raymond James	“Underperform” → “Market Perform” upgrade
2023-01-30	TD Cowen	“Market Perform” → “Outperform” upgrade
2023-01-20	J.P. Morgan	“Neutral” → “Overweight” upgrade
2022-10-26	Raymond James	“Market Perform” → “Underperform” downgrade
2022-10-17	Evercore ISI	“Outperform” → “In Line” downgrade
2022-09-09	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2022-09-09	Jefferies	“Underperform” → “Hold” upgrade
2022-07-25	Leerink Partners	“Outperform” → “Market Perform” downgrade
2022-01-05	Bank of America	“Neutral” → “Underperform” downgrade
2022-01-03	Bernstein	“Market Perform” → “Outperform” upgrade
2021-12-15	Bernstein	“Outperform” → “Market Perform” downgrade
2021-11-05	Benchmark	“Buy” → “Hold” downgrade
2021-01-25	BMO Capital	“Market Perform” → “Outperform” upgrade
2021-01-13	Benchmark	“Hold” → “Buy” upgrade
2020-10-05	Cantor Fitzgerald	“Neutral” → “Overweight” upgrade
2020-08-20	Benchmark	“Buy” → “Hold” downgrade
2020-07-09	Truist	“Hold” → “Buy” upgrade
2020-05-26	Wells Fargo	“Equal Weight” → “Overweight” upgrade
2020-04-28	Citigroup	“Buy” → “Neutral” downgrade
2020-04-17	Benchmark	“Hold” → “Buy” upgrade
2020-03-04	CFRA	“Buy” → “Hold” downgrade
2020-02-26	Baird	“Outperform” → “Neutral” downgrade
2020-02-26	Canaccord Genuity	“Hold” → “Buy” upgrade
2020-02-25	Jefferies	“Hold” → “Buy” upgrade
2020-02-25	Evercore ISI	“In Line” → “Outperform” upgrade
2020-02-11	Argus Research	“Hold” → “Buy” upgrade
2019-12-24	Raymond James	“Market Perform” → “Perform” revised
2019-12-16	Evercore ISI	“Outperform” → “In Line” downgrade
2019-12-13	Credit Suisse	“Neutral” → “Outperform” upgrade
2019-11-07	Citigroup	“Neutral” → “Buy” upgrade
2019-09-23	Guggenheim	“Neutral” → “Buy” upgrade
2019-08-07	Baird	“Neutral” → “Outperform” upgrade
2019-06-18	Argus Research	“Buy” → “Hold” downgrade
2019-02-22	Guggenheim	“Buy” → “Neutral” downgrade
2019-01-04	Guggenheim	“Neutral” → “Buy” upgrade
2018-12-14	Goldman Sachs	“Neutral” → “Buy” upgrade
2018-08-03	Baird	“Outperform” → “Neutral” downgrade
2018-06-27	Oppenheimer	“Perform” → “Outperform” upgrade
2018-05-01	Guggenheim	“Buy” → “Neutral” downgrade
2018-04-09	Raymond James	“Outperform” → “Market Perform” downgrade
2018-02-21	Canaccord Genuity	“Buy” → “Hold” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.